Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
The training program underscores the importance of surgeon education in bringing novel therapies to market. By providing hands-on experience, Regentis aims to ensure that orthopedic surgeons are comfortable with the implantation technique and can deliver optimal outcomes for patients. The Centers of Excellence will serve as hubs for training and ongoing support, facilitating knowledge exchange among clinicians.
GelrinC addresses a significant market need. According to Regentis, approximately 470,000 cases of knee cartilage repair occur annually in the U.S., where no off-the-shelf treatment is currently available. GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. This technology could offer a simpler, single-step alternative to existing treatments that often require cell harvesting or multiple surgeries.
The commercial launch in Europe follows CE Mark approval, which allows the product to be marketed in the European Economic Area. Regentis is now focusing on building the infrastructure for commercial success, including surgeon training, supply chain logistics, and market access strategies. The company's regenerative medicine platform, based on synchronized degradable hydrogel implants, has potential applications beyond orthopedics, but the initial focus is on knee cartilage repair.
Investors and industry observers will be watching the rollout closely, as successful commercialization could validate the Gelrin platform and open doors for additional indications. The company’s progress in Europe may also inform its strategy for the U.S. market, where regulatory pathways are still being explored. For more information, visit the company's newsroom at https://ibn.fm/RGNT.
